Mas Financial Services Regulatory Approval

Mas Financial Services Earnings Call Transcript: Key Takeaways

MAS Financial continues its consistent growth trajectory, crossing the ₹17,000 crore AUM milestone. Management remains confident in achieving a ₹1 lakh crore AUM by 2036 while maintaining robust asset quality and capital adequacy.

Call

Guides 25% growth

Mas Financial Services Investor Presentation: Key Takeaways

Q2FY27: consolidated AUM ₹17,043 Cr (+23.31% YoY), consolidated PAT ₹115 Cr (+25.91% YoY); ROE 15.33%, cost of borrowing 9.19%, MSME-focused lending.

Mas Financial Services Debt & Borrowing

MAS Financial Services confirmed 100% security cover over its secured NCDs as at 30 September 2026. The auditor-certified statement shows cover of 1.11 on book value.

Mas Financial Services Results Update

MAS Financial Services reported Q2 FY27 consolidated PAT of ₹115.12 Crores, up 25.91% YoY, with AUM at ₹17,042.86 Crores. Standalone PAT was ₹110.05 Crores on ~23% growth.

Mas Financial Services Q2 FY27 Results: Net Profit ₹115.1 Cr, Up 25.9% YoY

Mas Financial Services Ltd reported revenue from operations of ₹589.4 Cr (+22.7% YoY) and net profit of ₹115.1 Cr (+25.9% YoY) for Q2 FY27.

Key figure

Net profit ₹115.1 Cr · +25.9% YoY

Mas Financial Services Board Meeting Date

MAS Financial Services has scheduled a board meeting for October 28, 2026, to consider financial results for the quarter and half-year ended September 30, 2026.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.

Emmbi Industries Regulatory Approval

SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.

Bliss GVS Pharma Regulatory Approval

Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.

John Cockerill India Regulatory Approval

John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.